NEW YORK, Dec. 21, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The negative economic climate has meant that governments and payors alike are looking at reducing the prices of drugs as one way to contain costs. This has particularly affected areas where there is strong competition as with commodity generics. This report assesses the potential of new supergenerics in the setting of specific therapeutic classes. The report identifies the drivers and resistors for developing supergenerics in different countries and regions, and evaluates regulatory issues that hamper or encourage the development of supergenerics. It also evaluates the different company types that are involved in the supergeneric sector.
Scope of this research
Research and analysis Highlights The report identifies that there is still considerable scope for gaining price premiums for supergenerics in most areas studied. Although price premiums are obtainable in free price setting markets like the US the situation in the EU is complicated and reimbursement levels may pose another hurdle for SG producers in the diverse EU market place.
SG producers have been forced to focus on areas of unmet medical need and high sales potential markets such as the CNS area, as innovative companies have already patented widely and developed many line extensions in more obvious and easy to formulate areas such as cardiovascular, with single isomers, combinations, extended release, and prodrugs.
There are considerable opportunities for licensing products for wider markets as often SG producers concentrate on just one market and require licensing partners to reach other geographic areas and will usually have no access to emerging markets which offer potential for SG sales.
Key reasons to purchase this research
To order this report:: Market Opportunities for Supergenerics
Copyright©2010 PR Newswire.
All rights reserved